Sai Life Sciences has released robust financial results for the third quarter (Q3) and nine months (9M) ending December 31, 2024.

The company reported a 15 percent increase in revenue and a 36 percent rise in net profit compared to the same period last year, driven by strong execution, expanding capacity, and deepening customer relationships.

For Q3 FY25, revenue from operations stood at INR 439.8 crore, marking a 14.6 percent increase from INR 383.6 crore in Q3 FY24. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) rose to INR 124.5 crore, reflecting a 19.5 percent growth from INR 104.2 crore in the previous year’s quarter. The net profit (PAT) surged to INR 53.9 crore, up from INR 39.6 crore in Q3 FY24, showcasing a 36 percent year-on-year growth.

For the nine-month period (9M FY25), revenue reached INR 1,115.1 crore, reflecting an 8.7 percent increase compared to INR 1,026 crore in 9M FY24. EBITDA surged to INR 264 crore, a significant 50 percent increase from INR 176 crore last year. Meanwhile, PAT soared to INR 81.9 crore, marking a 206.8 percent rise from INR 26.7 crore in the corresponding period of FY24.

Commenting on the results, Krishna Kanumuri, Managing Director and CEO of Sai Life Sciences, highlighted the company’s commitment to innovation and customer-centric solutions. He emphasized the growing demand for integrated CRDMO services in the pharmaceutical and biotech sectors, positioning the company as a key player in global drug development. He also noted that with major pharmaceutical companies diversifying their supply chains beyond China, India stands at the forefront of this transformation.

Siva Chittor, Chief Financial Officer, underscored the company's focus on operational discipline and strategic investments. He noted that despite rising employee costs, the company maintained financial stability and reduced debt obligations significantly. As of December 2024, Sai Life Sciences had repaid INR 585.7 crore out of its planned INR 720 crore IPO proceeds, with the remaining amount settled in January 2025, leading to an anticipated reduction in interest costs.

Looking ahead, Sai Life Sciences remains committed to expanding its service offerings, investing in technology, and enhancing operational efficiencies to sustain its growth momentum. The company will continue to leverage its strong market presence and robust order pipeline to drive long-term value for stakeholders.